Cargando…

The proprotein convertase PC1/3 regulates TLR9 trafficking and the associated signaling pathways

Endosomal TLR9 is considered as a potent anti-tumoral therapeutic target. Therefore, it is crucial to decipher the mechanisms controlling its trafficking since it determines TLR9 activation and signalling. At present, the scarcity of molecular information regarding the control of this trafficking an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Duhamel, M., Rodet, F., Murgoci, A. N., Desjardins, R., Gagnon, H., Wisztorski, M., Fournier, I., Day, R., Salzet, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4725977/ https://www.ncbi.nlm.nih.gov/pubmed/26778167 http://dx.doi.org/10.1038/srep19360

Ejemplares similares

Proprotein convertase 1/3 inhibited macrophages: A novel therapeutic based on drone macrophages
por: Duhamel, Marie, et al.
Publicado: (2016)

The Role of Proprotein Convertases in the Regulation of the Function of Immune Cells in the Oncoimmune Response
por: Rose, Mélanie, et al.
Publicado: (2021)

Proprotein Convertase 1/3 (PC1/3) in the Rat Alveolar Macrophage Cell Line NR8383: Localization, Trafficking and Effects on Cytokine Secretion
por: Gagnon, Hugo, et al.
Publicado: (2013)

The Role of a Proprotein Convertase Inhibitor in Reactivation of Tumor-Associated Macrophages and Inhibition of Glioma Growth
por: Rose, Mélanie, et al.
Publicado: (2020)

Implications of Proprotein Convertases in Ovarian Cancer Cell Proliferation and Tumor Progression: Insights for PACE4 as a Therapeutic Target()
por: Longuespée, Rémi, et al.
Publicado: (2014)

Hysteretic Behavior of Proprotein Convertase 1/3 (PC1/3)
por: Icimoto, Marcelo Y., et al.
Publicado: (2011)

The isoforms of proprotein convertase PC5 are sorted to different subcellular compartments
Publicado: (1996)

Abnormal expression and processing of the proprotein convertases PC1 and PC2 in human colorectal liver metastases
por: Tzimas, George N, et al.
Publicado: (2005)

Discovery of the Proprotein Convertases and their Inhibitors
por: Khatib, Abdel-Majid, et al.
Publicado: (2006)

Proprotein Convertases and the Complement System
por: Dobó, József, et al.
Publicado: (2022)

Comparative analysis of expression of the proprotein convertases furin, PACE4, PC1 and PC2 in human lung tumours.
por: Mbikay, M., et al.
Publicado: (1997)

Is there a link between proprotein convertase PC7 activity and human lipid homeostasis?
por: Guillemot, Johann, et al.
Publicado: (2014)

Identification of Novel Proteins Interacting with Proprotein Convertase Subtilisin/Kexin 9
por: Melendez, Quantil M., et al.
Publicado: (2020)

The proprotein convertase PC5/6 is protective against intestinal tumorigenesis: in vivo mouse model
por: Sun, Xiaowei, et al.
Publicado: (2009)

The proprotein convertase furin is required for trophoblast syncytialization
por: Zhou, Z, et al.
Publicado: (2013)

Proprotein Convertase Subtilisin/Kexin Type 9 and Inflammation: An Updated Review
por: Wu, Na-Qiong, et al.
Publicado: (2022)

Proprotein convertases in high-density lipoprotein metabolism
por: Choi, Seungbum, et al.
Publicado: (2013)

Characterization of Proprotein Convertases and Their Involvement in Virus Propagation
por: Garten, Wolfgang
Publicado: (2018)

Testicular Germ Cell Tumours and Proprotein Convertases
por: Velado-Eguskiza, Aitziber, et al.
Publicado: (2022)

The Role of Proprotein Convertases in Upper Airway Remodeling
por: Lee, Sang-Nam, et al.
Publicado: (2022)

Proprotein Convertases Process Pmel17 during Secretion
por: Leonhardt, Ralf M., et al.
Publicado: (2011)

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders
por: O’Connell, Emma M., et al.
Publicado: (2020)

Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9)
por: Schulz, Rainer, et al.
Publicado: (2015)

Plasma Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in the Acute Respiratory Distress Syndrome
por: Metkus, Thomas S., et al.
Publicado: (2022)

Epigenetic Studies Revealed a Ghost Proteome in PC1/3 KD Macrophages under Antitumoral Resistance Induced by IL-10
por: Cardon, Tristan, et al.
Publicado: (2020)

Effect of cilostazol on plasma levels of proprotein convertase subtilisin/kexin type 9
por: Chen, I-Chih, et al.
Publicado: (2017)

Proprotein convertase subtilisin/kexin type 9: an update on the cardiovascular outcome studies
por: Ferri, Nicola, et al.
Publicado: (2020)

Effects of proprotein convertase subtilisin/kexin type-9 inhibitors on fatty liver
por: Shafiq, Muhammad, et al.
Publicado: (2020)

Proprotein Convertase Subtilisin/Kexin 9 as a Modifier of Lipid Metabolism in Atherosclerosis
por: Poznyak, Anastasia V., et al.
Publicado: (2023)

PC1/3 KD Macrophages Exhibit Resistance to the Inhibitory Effect of IL-10 and a Higher TLR4 Activation Rate, Leading to an Anti-Tumoral Phenotype
por: Rodet, Franck, et al.
Publicado: (2019)

OFF-State-Specific Inhibition of the Proprotein Convertase Furin
por: Dahms, Sven O., et al.
Publicado: (2021)

What Are the Roles of Proprotein Convertases in the Immune Escape of Tumors?
por: Mehranzadeh, Elham, et al.
Publicado: (2022)

Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9
por: Jang, Hyun-Duk, et al.
Publicado: (2020)

Furin Is the Major Proprotein Convertase Required for KISS1-to-Kisspeptin Processing
por: Harihar, Sitaram, et al.
Publicado: (2014)

Plasma levels of the proprotein convertase furin and incidence of diabetes and mortality
por: Fernandez, C., et al.
Publicado: (2018)

In Vivo Analysis of the Contribution of Proprotein Convertases to the Processing of FGF23
por: Al Rifai, Omar, et al.
Publicado: (2021)

Molecular characterization of proprotein convertase subtilisin/kexin type 9-mediated degradation of the LDLR
por: Wang, Yan, et al.
Publicado: (2012)

Hypercholesterolemia, low density lipoprotein receptor and proprotein convertase subtilisin/kexin-type 9
por: Gu, Hong-mei, et al.
Publicado: (2015)

The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease
por: Kim, Eun Ji, et al.
Publicado: (2020)

Variations of the proprotein convertase subtilisin/kexin type 9 gene in coronary artery disease
por: Chiang, Shih-Min, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pgfs807l2f2t9am1b0hlvc3f4c